J&J reach $20.4m settlement agreement over opioid trial
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
List view / Grid view
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
Large-value deals are a new strategy for stakeholders to capitalise on the strengths of other companies and to overcome barriers to financial success.
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
Purdue has filed for bankruptcy protection after a settlement offer from the company over the opioid crisis was rejected by 24 states.
A settlement has purportedly been agreed between Purdue Pharma and 23 US states to resolve the opioid crisis case against the company.
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
A report has found that the rejection of a settlement offer from Purdue has led to the company arranging to file for bankruptcy.
An annual report has found that the pharmaceutical sector is the lowest regarded industry among US citizens.
The two pharma companies have agreed to pay $15 million to certain Ohio counties before an opioid abuse trial to be held in October.
The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
New research has found that of the 38 warning letters handed out by the FDA in 2019, the US and India received the vast majority.
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
Pharma contract placement was found to increase by 250 percent compared to last year, according to figures from a recruitment firm.